Healthtech · Pre-seed
Sigrun Diagnostics
A blood test that flags sepsis twelve hours earlier. Raising pre-seed capital to expand after two-hospital pilot.
Round progress
••• of $900,000
Instrument
Equity
Min cheque
$25K
Valuation cap
•••
Deadline
97 days
Committed capital and the valuation cap open after sign-in.
Problem
Sepsis kills because it is identified hours too late in emergency departments.
Solution
A host-response biomarker panel that runs on existing hospital analysers.
Traction
Two-hospital pilot, 1,400 samples, 91% sensitivity in retrospective study.
Team
Karolinska clinicians and a proteomics founder; 8 people.
Use of funds
60% engineering and product, 25% go-to-market hires, 15% compliance and working capital.
Early-stage investing carries a high risk of losing all capital. GAIN does not hold investor funds and does not give investment, legal or tax advice.